share_log

Novavax | 10-Q: Q3 2024 Earnings Report

Novavax | 10-Q: Q3 2024 Earnings Report

诺瓦瓦克斯医药 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/12 16:14

Moomoo AI 已提取核心信息

Novavax reported Q3 2024 revenue of $84.5 million, down from $187.0 million in Q3 2023, with product sales rising to $38.2 million from $2.2 million. The quarter saw licensing and royalty revenue of $46.3 million, including $32.7 million from the Sanofi collaboration. Net loss narrowed to $121.3 million or $0.76 per share, compared to $130.8 million or $1.26 per share last year.The company strengthened its financial position through a strategic partnership with Sanofi, receiving a $500 million upfront payment and potential milestone payments up to $700 million. Operating expenses decreased 30% year-over-year to $218.5 million, reflecting cost reduction initiatives. Cash and investments totaled $924.5 million as of September 30, 2024.Looking ahead, Novavax is advancing its COVID-19 vaccine program with recent authorizations in the US and EU for its 2024-2025 updated vaccine. The company continues to evolve its operating model focusing on the Sanofi partnership, pipeline development including COVID-Influenza combination vaccine, and leveraging its Matrix-M adjuvant technology platform while implementing further cost reductions.
Novavax reported Q3 2024 revenue of $84.5 million, down from $187.0 million in Q3 2023, with product sales rising to $38.2 million from $2.2 million. The quarter saw licensing and royalty revenue of $46.3 million, including $32.7 million from the Sanofi collaboration. Net loss narrowed to $121.3 million or $0.76 per share, compared to $130.8 million or $1.26 per share last year.The company strengthened its financial position through a strategic partnership with Sanofi, receiving a $500 million upfront payment and potential milestone payments up to $700 million. Operating expenses decreased 30% year-over-year to $218.5 million, reflecting cost reduction initiatives. Cash and investments totaled $924.5 million as of September 30, 2024.Looking ahead, Novavax is advancing its COVID-19 vaccine program with recent authorizations in the US and EU for its 2024-2025 updated vaccine. The company continues to evolve its operating model focusing on the Sanofi partnership, pipeline development including COVID-Influenza combination vaccine, and leveraging its Matrix-M adjuvant technology platform while implementing further cost reductions.
诺瓦瓦克斯医药报告2024年第三季度营业收入为8450万美元，较2023年第三季度的18700万美元下降，产品销售从220万美元上升至3820万美元。该季度许可和特许权使用费收入为4630万美元，其中3270万美元来自赛诺菲安万特的合作。净亏损缩窄至12130万美元或每股0.76美元，去年为13080万美元或每股1.26美元。公司通过与赛诺菲安万特的战略合作加强了财务状况，获得了50000万美元的预付款以及最高可达70000万美元的潜在里程碑付款。营业费用同比减少30%，降至21850万美元，反映了成本削减举措。截至2024年9月30日，现金和投资总额为92450万美元。展望未来，诺瓦瓦克斯医...展开全部
诺瓦瓦克斯医药报告2024年第三季度营业收入为8450万美元，较2023年第三季度的18700万美元下降，产品销售从220万美元上升至3820万美元。该季度许可和特许权使用费收入为4630万美元，其中3270万美元来自赛诺菲安万特的合作。净亏损缩窄至12130万美元或每股0.76美元，去年为13080万美元或每股1.26美元。公司通过与赛诺菲安万特的战略合作加强了财务状况，获得了50000万美元的预付款以及最高可达70000万美元的潜在里程碑付款。营业费用同比减少30%，降至21850万美元，反映了成本削减举措。截至2024年9月30日，现金和投资总额为92450万美元。展望未来，诺瓦瓦克斯医药正在推进其COVID-19生物-疫苗项目，最近在美国和欧盟获得了2024-2025年更新生物-疫苗的授权。公司持续优化其运营模式，专注于与赛诺菲安万特的合作、管道开发（包括COVID-流感组合生物-疫苗）以及利用其Matrix-m佐剂技术平台，同时实施进一步的成本削减。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股集体大涨！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 $阿里巴巴 (BABA.US)$ 、 $京东 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股价格飙升，市场情绪火热。 🎙️讨论： Deepseek 展开
    中国股票的疯狂反弹暂停？华尔街仍在大举押注热门股票